Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
48 results
  • Thymoma, Rectal Cancer, Ovarian Cancer, Melanoma, Colorectal Cancer, Kidney Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Lung Cancer

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers

  • Lung Cancer

24-095          Phase III

A study of repotrectinib versus crizotinib in participants with locally advanced or metastatic tyrosine kinase inhibitor (tki)-naïve ros1-positive non-small cell lung cancer (nsclc) (trident-3)

  • Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer

23-242          Phase I

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination with Pembrolizumab in Adults with Locally Advanced or Metastatic Solid Tumors

  • Lung Cancer, Melanoma, Metastatic/Advanced Cancer, Head and Neck Cancer, Kidney Cancer

22-614          Phase I

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

  • Endometrial Cancer, Melanoma, Colorectal Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Bladder Cancer

24-203          Phase I

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

  • Lung Cancer

24-498          Phase I

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

  • Lung Cancer

23-036          Phase I

An open-label, multicenter, dose escalation and dose expansion phase 1/2 study with PT217 followed by a key chemotherapy and/or checkpoint inhibitor combination in patients with neuroendocrine carcinomas that are known to be DLL3 expressing cancers

  • Lung Cancer

19-825          N/A

An open-label, multi-center, global, rollover study for patients who have previously been treated with capmatinib (INC280)as monotherapy or in combination in a Novartis Sponsored trial

  • Colorectal Cancer, Lung Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Breast Cancer

22-499          Phase I

An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2

  • Lung Cancer

21-497          Phase I

An Open-Label, Multi-Center, Phase I Study of Oral IAG933 in Adult Patients with Advanced Mesothelioma and Other Solid Tumors

Showing 31 - 40 of 48 results